Fortune 500 Tuesday, 01/29/19 08:54:34 PM Re: None Post # of 141 Yes, Myl has spent money to make money . They even added a sales force . The doctors now need to learn how to spell FULPHILA ( 4 billion dollar market)! THE first biosimilar (Neulasta). This biosimilar idea is still good for our government taxes , insurance companies and patients . Not substitutable but eventually the insurance companies will force the issue with the prior auth system that is inplace . Teva has Rituimab and I believe Mylan will have that 7 billion dollar market soon with them . The future looks better for Mylan and the price is right !